Hi xxxxx As a follow-up to your email, att
Post# of 72

As a follow-up to your email, attached is recent information as filed with the SEC, and a corresponding press release about our current plans for Gene Biotherapeutics and our lead product candidate Generx [Ad5FGF-4] that is being developed for the potential treatment of patients with refractory angina.
Regards,
Chris Reinhard

